Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy

Huiying He, Liang Cheng, Lawrence M. Weiss, Peiguo G. Chu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Incidental pelvic node malignant B-cell lymphomas diagnosed at the time of radical prostatectomy are rare. Their clinical outcome has not been studied. We studied thirteen such cases with long-term clinical follow-up. Patients were followed between 9 and 94 months after surgery. Of 13 cases, 9 were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 3 marginal zone B-cell lymphoma (MZL) and 1 mantle cell lymphoma (MCL). All 13 patients did not receive radiation or chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma progression between 1 and 5 months after radical prostatectomy. After progression, the mantle cell lymphoma patient received aggressive chemotherapy and had systemic dissemination. Two of 13 cases had recurrent prostate carcinoma. None of 13 patients had died from lymphoma or prostate carcinoma at the last follow-up. In conclusion, most incidental pelvic node lymphomas (8/13) showed no evidence of systemic dissemination to peripheral blood or bone marrow after a mean 42.8 weeks of follow-up despite the fact that no additional treatment was given. Strong consideration should be given to withholding further treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the time of radical prostatectomy until disease progression occurs.

Original languageEnglish
Pages (from-to)1976-1980
Number of pages5
JournalLeukemia and Lymphoma
Volume48
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

B-Cell Lymphoma
Prostatectomy
Mantle-Cell Lymphoma
Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Prostate
Carcinoma
Drug Therapy
Marginal Zone B-Cell Lymphoma
Withholding Treatment
Non-Hodgkin's Lymphoma
Disease Progression
Bone Marrow
Radiation

Keywords

  • B-cell lymphoma
  • Pelvic lymph node
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy. / He, Huiying; Cheng, Liang; Weiss, Lawrence M.; Chu, Peiguo G.

In: Leukemia and Lymphoma, Vol. 48, No. 10, 10.2007, p. 1976-1980.

Research output: Contribution to journalArticle

@article{bc29b17ba1c84353899e7a8affdfe999,
title = "Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy",
abstract = "Incidental pelvic node malignant B-cell lymphomas diagnosed at the time of radical prostatectomy are rare. Their clinical outcome has not been studied. We studied thirteen such cases with long-term clinical follow-up. Patients were followed between 9 and 94 months after surgery. Of 13 cases, 9 were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 3 marginal zone B-cell lymphoma (MZL) and 1 mantle cell lymphoma (MCL). All 13 patients did not receive radiation or chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma progression between 1 and 5 months after radical prostatectomy. After progression, the mantle cell lymphoma patient received aggressive chemotherapy and had systemic dissemination. Two of 13 cases had recurrent prostate carcinoma. None of 13 patients had died from lymphoma or prostate carcinoma at the last follow-up. In conclusion, most incidental pelvic node lymphomas (8/13) showed no evidence of systemic dissemination to peripheral blood or bone marrow after a mean 42.8 weeks of follow-up despite the fact that no additional treatment was given. Strong consideration should be given to withholding further treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the time of radical prostatectomy until disease progression occurs.",
keywords = "B-cell lymphoma, Pelvic lymph node, Prognosis",
author = "Huiying He and Liang Cheng and Weiss, {Lawrence M.} and Chu, {Peiguo G.}",
year = "2007",
month = "10",
doi = "10.1080/10428190701584007",
language = "English",
volume = "48",
pages = "1976--1980",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Clinical outcome of incidental pelvic node malignant B-cell lymphomas discovered at the time of radical prostatectomy

AU - He, Huiying

AU - Cheng, Liang

AU - Weiss, Lawrence M.

AU - Chu, Peiguo G.

PY - 2007/10

Y1 - 2007/10

N2 - Incidental pelvic node malignant B-cell lymphomas diagnosed at the time of radical prostatectomy are rare. Their clinical outcome has not been studied. We studied thirteen such cases with long-term clinical follow-up. Patients were followed between 9 and 94 months after surgery. Of 13 cases, 9 were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 3 marginal zone B-cell lymphoma (MZL) and 1 mantle cell lymphoma (MCL). All 13 patients did not receive radiation or chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma progression between 1 and 5 months after radical prostatectomy. After progression, the mantle cell lymphoma patient received aggressive chemotherapy and had systemic dissemination. Two of 13 cases had recurrent prostate carcinoma. None of 13 patients had died from lymphoma or prostate carcinoma at the last follow-up. In conclusion, most incidental pelvic node lymphomas (8/13) showed no evidence of systemic dissemination to peripheral blood or bone marrow after a mean 42.8 weeks of follow-up despite the fact that no additional treatment was given. Strong consideration should be given to withholding further treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the time of radical prostatectomy until disease progression occurs.

AB - Incidental pelvic node malignant B-cell lymphomas diagnosed at the time of radical prostatectomy are rare. Their clinical outcome has not been studied. We studied thirteen such cases with long-term clinical follow-up. Patients were followed between 9 and 94 months after surgery. Of 13 cases, 9 were chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 3 marginal zone B-cell lymphoma (MZL) and 1 mantle cell lymphoma (MCL). All 13 patients did not receive radiation or chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma progression between 1 and 5 months after radical prostatectomy. After progression, the mantle cell lymphoma patient received aggressive chemotherapy and had systemic dissemination. Two of 13 cases had recurrent prostate carcinoma. None of 13 patients had died from lymphoma or prostate carcinoma at the last follow-up. In conclusion, most incidental pelvic node lymphomas (8/13) showed no evidence of systemic dissemination to peripheral blood or bone marrow after a mean 42.8 weeks of follow-up despite the fact that no additional treatment was given. Strong consideration should be given to withholding further treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the time of radical prostatectomy until disease progression occurs.

KW - B-cell lymphoma

KW - Pelvic lymph node

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=35148826953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148826953&partnerID=8YFLogxK

U2 - 10.1080/10428190701584007

DO - 10.1080/10428190701584007

M3 - Article

C2 - 17917966

AN - SCOPUS:35148826953

VL - 48

SP - 1976

EP - 1980

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -